GLTO
Galecto, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.58
−3.36%Aug 5, 2026, 12:00 UTC
Damora Therapeutics initiated the global Phase 1/1b CLARITY-101 clinical trial of DMR-001 in patients with mutant calreticulin-driven essential thrombocythemia and myelofibrosis, following health authority approval.
Source:Jul 17, 2026, 12:00 UTC
Damora Therapeutics completed its redomestication from Delaware to the Cayman Islands, effective July 16, 2026.
Source: